Does Rallies show Form 4 insider transactions for RCUS?

Yes. Rallies tracks RCUS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RCUS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RCUS. It does not provide personalized investment advice.

RCUS (Arcus Biosciences, Inc.) Stock Analysis - Insider Trades

Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of May 21, 2026, RCUS trades at $23.82 with a market cap of $2.94B and a P/E ratio of -7.37. RCUS moved +4.48% today. Year to date, RCUS is +9.05%; over the trailing twelve months it is +167.64%. Its 52-week range spans $6.50 to $28.72. Analyst consensus is strong buy with an average price target of $35.89. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RCUS stock inside the company?

Recent RCUS insider activity includes Jaen Juan C. sold 29.67K, Jaen Juan C. sold 2.05K, Jaen Juan C. sold 100, Goeltz II Robert C. sold 6.55K, and Azoy Alexander sold 4.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RCUS Key Metrics

Key financial metrics for RCUS
Metric	Value
Price	$23.82
Market Cap	$2.94B
P/E Ratio	-7.37
EPS	$-3.19
Dividend Yield	0.00%
52-Week High	$28.72
52-Week Low	$6.50
Volume	109
Avg Volume	0
Revenue (TTM)	$236.00M
Net Income	$-369.00M
Gross Margin	0.00%

Recent RCUS Insider Trades

Jaen Juan C. sold 29.67K (~$633.16K) on Jan 5, 2026.
Jaen Juan C. sold 2.05K (~$45.86K) on Jan 5, 2026.
Jaen Juan C. sold 100 (~$2.32K) on Jan 5, 2026.
Goeltz II Robert C. sold 6.55K (~$153.19K) on Dec 31, 2025.
Azoy Alexander sold 4.34K (~$96.61K) on Dec 18, 2025.

Latest RCUS News

Arcus Casdatifan Shows 45% ORR, 15.1-Month PFS and $1B Cash; PEAK-1 Enrollment Underway — Feb 28, 2026
Arcus Biosciences Shares Surge 88.2% While 2026 Loss Estimate Narrows — Feb 27, 2026
Arcus Biosciences Ends Q4 with $400M+ Cash, Prepares for Phase II Readouts — Feb 26, 2026
Arcus Biosciences Reports Over 12-Month PFS in Late-Line Kidney Cancer — Feb 23, 2026
Arcus Biosciences Price Target Cut to $23 Over Welireg Concerns; Goldman Sachs Sees $28 — Feb 19, 2026

RCUS Analyst Consensus

10 analysts cover RCUS: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.89.

Common questions about RCUS

Who is trading RCUS stock inside the company?: Recent RCUS insider activity includes Jaen Juan C. sold 29.67K, Jaen Juan C. sold 2.05K, Jaen Juan C. sold 100, Goeltz II Robert C. sold 6.55K, and Azoy Alexander sold 4.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RCUS?: Yes. Rallies tracks RCUS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RCUS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RCUS. It does not provide personalized investment advice.